ARCA biopharma Inc ABIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABIO is a good fit for your portfolio.
News
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate ABIO, MODN, DPSI, AIRC
-
Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, HIBB, ABIO, HMNF
-
Kuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law Firm
-
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PIK, CHX, MODN, ABIO
-
ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
Trading Information
- Previous Close Price
- $3.07
- Day Range
- $3.01–3.29
- 52-Week Range
- $1.56–4.49
- Bid/Ask
- $3.05 / $3.15
- Market Cap
- $45.55 Mil
- Volume/Avg
- 124,748 / 97,925
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.arcabio.com
Valuation
|
Metric
|
ABIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABIO
|
|---|---|
Quick Ratio | 22.71 |
Current Ratio | 23.19 |
Interest Coverage | — |
Quick Ratio
ABIO
Profitability
|
Metric
|
ABIO
|
|---|---|
Return on Assets (Normalized) | −13.73% |
Return on Equity (Normalized) | −14.24% |
Return on Invested Capital (Normalized) | −19.35% |
Return on Assets
ABIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Dxvcxvfzgf | Glr | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tvbnchls | Ykpdlw | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Thbcsxnh | Bqdzhbt | $118.7 Bil | |||
| Moderna Inc
MRNA
| Wpfpcrpd | Kqxy | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mxvjccpv | Zxxwd | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Mllhjfy | Zknhw | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ywxxtsj | Xhw | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Myjdxnpw | Rlwfky | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ryfxvwfg | Mllt | $15.0 Bil | |||
| Incyte Corp
INCY
| Sjxmkzqsq | Mrmcffs | $13.5 Bil |